Orexo AB announced the signing of an agreement with Dexcel Pharma to divest the full US rights to Zubsolv (buprenorphine/naloxone) sublingual tablet CIII, for the treatment of opioid… read more.
Indivior PLC announced that the FDA has approved label changes for Sublocade (buprenorphine extended-release ) including a rapid initiation protocol and alternative injection sites, marking a significant advancement… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
